Falla un medicamento de Novartis contra el COVID-19
El grupo farmacéutico suizo Novartis anunció el lunes que los ensayos clínicos con ruxolitinib no mostraron mejoras en casos severos de COVID-19. (Fuente: AFP)
- Redacción Ojo
- 14 de diciembre de 2020 05:31 p.m.
:quality(75)/cdn.jwplayer.com/v2/media/P4LCGlqi/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/3qFLvrYt/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/eFUyMiiG/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9xzlPJQd/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/nRTmicLr/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/asozLCSI/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/O0BogLHd/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/otzBpxzl/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/eOLGiQpH/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/D1z3Aq5M/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/gupVjRth/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/F84n2FhT/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6W1CraYa/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/tnLwbLWX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/uK0fQiBn/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/65qXCx1U/poster.jpg)